S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.40
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages

Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

$14.82
+0.72 (+5.11%)
(As of 03/28/2024 ET)
Today's Range
$14.10
$15.18
50-Day Range
$7.59
$17.47
52-Week Range
$3.21
$18.33
Volume
6.19 million shs
Average Volume
8.24 million shs
Market Capitalization
$4.14 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.64

Iovance Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
66.2% Upside
$24.64 Price Target
Short Interest
Bearish
21.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.34mentions of Iovance Biotherapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Acquiring Shares
$2.29 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.40) to ($0.72) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.76 out of 5 stars

Medical Sector

59th out of 939 stocks

Biological Products, Except Diagnostic Industry

9th out of 155 stocks

IOVA stock logo

About Iovance Biotherapeutics Stock (NASDAQ:IOVA)

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops products for the treatment of advanced melanoma, non-small cell lung cancer, gynecological cancers, and solid tumor cancers, which include TILVANCE-301, LN-145, IOV-LUN-202, IOV-COM-202, C-145-03, IOV-4001, IOV-3001, IOV-GM1-201, IOV-CLL-01, IOV-2001, and C-145-04. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Stock Price History

IOVA Stock News Headlines

CBOE shift unlocks new weekend income strategy
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend.
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 1.7%
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
7 Biotech Stocks Ready to Ride the Sector's Resurgence
See More Headlines
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IOVA
Fax
N/A
Employees
557
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$24.64
High Stock Price Target
$34.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+66.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-444,040,000.00
Pretax Margin
-37,638.01%

Debt

Sales & Book Value

Annual Sales
$1.19 million
Book Value
$2.28 per share

Miscellaneous

Free Float
250,259,000
Market Cap
$4.14 billion
Optionable
Optionable
Beta
0.63

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Frederick G. Vogt Esq. (Age 50)
    J.D., Ph.D., Interim CEO, President, General Counsel & Corporate Secretary
    Comp: $1.39M
  • Mr. Jean-Marc Bellemin M.B.A. (Age 51)
    CFO, Principal Accounting Officer & Treasurer
    Comp: $932.2k
  • Dr. Igor P. Bilinsky (Age 51)
    Chief Operating Officer
    Comp: $932.2k
  • Dr. Friedrich Graf Finckenstein M.D. (Age 57)
    Chief Medical Officer
    Comp: $1.06M
  • Ms. Sara Pellegrino
    Vice President of Investor Relations & Public Relations
  • Ms. Tracy Winton
    Senior Vice President of Human Resources
  • Mr. Howard B. Johnson M.B.A. (Age 64)
    Chief Business Officer
  • Mr. James Ziegler M.B.A.
    Executive Vice President of Commercial
  • Dr. Raj K. Puri M.D.
    Ph.D., Executive VP of Regulatory Strategy & Translational Medicine
  • Mr. Brian Shew M.B.A.
    Senior VP & Head of Digital and Information Technology

IOVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IOVA shares.
View IOVA analyst ratings
or view top-rated stocks.

What is Iovance Biotherapeutics' stock price target for 2024?

10 Wall Street research analysts have issued 12 month target prices for Iovance Biotherapeutics' shares. Their IOVA share price targets range from $17.00 to $34.00. On average, they expect the company's stock price to reach $24.64 in the next twelve months. This suggests a possible upside of 66.2% from the stock's current price.
View analysts price targets for IOVA
or view top-rated stocks among Wall Street analysts.

How have IOVA shares performed in 2024?

Iovance Biotherapeutics' stock was trading at $8.13 at the beginning of 2024. Since then, IOVA stock has increased by 82.3% and is now trading at $14.82.
View the best growth stocks for 2024 here
.

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our IOVA earnings forecast
.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) posted its quarterly earnings data on Wednesday, February, 28th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.01. The biotechnology company earned $0.48 million during the quarter, compared to the consensus estimate of $1.44 million. During the same period in the prior year, the business posted ($0.64) EPS.

What ETFs hold Iovance Biotherapeutics' stock?
What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), Xtrackers California Municipal Bond ETF (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.91%), Vanguard Group Inc. (8.17%), Perceptive Advisors LLC (4.68%), Artisan Partners Limited Partnership (1.89%), Balyasny Asset Management L.P. (1.53%) and Goldman Sachs Group Inc. (1.44%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends
.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IOVA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners